Placeholder Banner

Letter to President Biden Discusses Collaboration To Boost Access to COVID-19 Treatments

BIO's Dr. Michelle McMurry-Heath pens new letter to the White House

March 8, 2021
Media Contact
JG
2027471281

Dr. Michelle McMurry-Heath, president and CEO of the Biotechnology Innovation Organization (BIO), sent a letter to President Biden outlining ways the public and private sectors can best work with global partners to ensure that patients around the world get access to COVID vaccines, therapeutics, and diagnostics.  

The letter, written on behalf of BIO members, highlights the importance of the COVAX and “ACT-Accelerator” initiatives to increase global vaccine access. It also makes clear industry concerns about the proposed “TRIPS waiver” in helping end this pandemic:

Dr. McMurry-Heath writes the TRIPs waiver would “distract from the need for coordinated international efforts and the cooperative work that currently is being advanced, and thus ultimately undermine the very goals of quick, safe access that it seeks to promote.”

She further notes:  

“The global pandemic can only be ended with global efforts that reach everywhere this deadly virus is prevalent […] BIO strongly supports strong, efficient, and effective efforts to see that successful COVID products get to patients everywhere in the world that need them.

“BIO looks forward to continuing its work with the Administration and other parties in developing policies that address global access considerations to COVID treatments and vaccines while also continuing to support innovative biotech research and development endeavors aimed at bringing this pandemic to an end as soon as possible.”

Read the full letter here or below.

Related Resources
Letter to President Joseph Biden - March 5 2021 .pdf
BIO COVID Parternships.March5_.pdf
Discover More
BIO President & CEO John F. Crowley announced today that BIO would take several important steps to reaffirm the organization’s position with regards to national security and the role that the industry plays as a vital strategic asset: “As a…
Following the conclusion of the WTO 13th Ministerial Conference in Abu Dhabi, John Murphy -- BIO's Chief Policy Officer -- made the following statement: “We are encouraged that WTO Members did not agree to extend an intellectual property…
The White House just announced plans to use Bayh-Dole “march-in rights” to step in and license patent rights of drugs “developed with federal funding” to other manufacturers when the price of the drug is deemed too high. BIO's Chief Advocacy Officer…